Original ArticleCharacteristics and Clinical Course of STEMI Patients who Received no Reperfusion in the Australia and New Zealand SNAPSHOT ACS Registry
Section snippets
Background
The use of reperfusion therapy in patients presenting with STEMI within 12 hours of symptom onset, is supported by some of the most powerful evidence in medicine, which has led to these therapies being given the highest levels of recommendations in international treatment guidelines [1], [2]. Primary PCI is the preferred treatment strategy if available in a timely period after patient presentation, but fibrinolytic therapy remains an effective and recommended strategy in many hospitals around
Study Design and Organisation
The SNAPSHOT ACS study was a prospective audit of consecutive patients admitted to 478 hospitals in Australia and New Zealand with suspected ACS during a two-week period. It was developed as a collaborative quality improvement initiative between the Cardiac Society of Australia and New Zealand, the Heart Foundation of Australia, the Australian Commission on Safety and Quality in Health Care, the George Institute for Global Health, and health networks or state governments in New South Wales,
Results
The SNAPSHOT ACS Registry enrolled 4387 patients, 419 of whom were diagnosed with STEMI. Primary PCI (PPCI) was performed in 160 patients (38.1%), fibrinolysis was administered in 105 (25.1%), and 154 (36.8%) did not receive reperfusion therapy (Figure 1). Forty-nine patients (11.7%) presented 12 hours or more after the onset of symptoms and were therefore not eligible for reperfusion therapy.
Discussion
The SNAPSHOT ACS Registry is the most broadly inclusive audit of ACS treatment in Australia and New Zealand with 4387 patients enrolled in a two-week period. This provided a unique opportunity to analyse reperfusion therapy for patients diagnosed with STEMI. We found that among 419 STEMI patients, 36.8% did not receive any reperfusion therapy.
However, among this cohort 28 patients underwent coronary angiography within 12 hours of symptom onset, but did not have primary PCI. This group of
Conclusions
The SNAPSHOT ACS Registry has indicated a small improvement in the proportion of STEMI patients with actual or attempted reperfusion. However, it has also highlighted that despite wider availability of PPCI, a considerable proportion of STEMI patients in Australia and New Zealand did not receive reperfusion therapy. In these patients almost a third presented after 12 hours. Those who did not receive reperfusion were generally older with complex comorbidities, and achieving an increase in the
Funding
The SNAPSHOT ACS study was supported in part by: The Cardiac Society of Australia and New Zealand; The Heart Foundation of Australia; The Agency for Clinical Innovation (NSW); the Victorian Cardiac Clinical Network; the Queensland Cardiac Clinical Network; the Western Australian Cardiac Clinical Network; and the South Australian Cardiac Clinical Network. The study was endorsed by the Australian Commission for Quality and Safety in Health Care.
Declaration of conflicting interests
Derek P. Chew: lecture fees AstraZeneca Australia; educational programme: Heart.org, John French: Advisory Board Membership Sanofi Aventis Australia, AstraZeneca Australia, Eli Lilly Australia and Boehringer Ingelheim; Grant In Aid; The Medicines Company. Chris Hammett: Consultancy Bayer Australia and Eli Lilly Australia; lecture fees Boehringer Ingelheim and Eli Lilly Australia; travel assistance AstraZeneca Australia, Bayer Australia, Boehringer Ingelheim Australia and Eli Lilly Australia,
Acknowledgements
We acknowledge the work of investigators in 478 hospitals throughout Australia and New Zealand who recruited patients for the SNAPSHOT ACS Registry.
References (19)
- et al.
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J Am Coll Cardiol.
(2013) - et al.
Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative
Am Heart J.
(2010) - et al.
Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006
Am Heart J.
(2008) - et al.
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial
Lancet
(2014) - et al.
Shorter ischaemic time and improved survival with pre-hospital STEMI diagnosis and direct transfer for primary PCI
Heart, Lung and Circulation.
(2015) - et al.
Patients’ understanding of their heart attack and the impact of exposure to a media campaign on pre-hospital time
Heart, Lung and Circulation.
(2015) Thrombolytic therapy in the elderly
Lancet.
(2000)- et al.
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
European Heart Journal.
(2012) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group
Lancet
(1994)
Cited by (11)
A fibrinolysis-first strategy for ST-elevation myocardial infarction in the COVID-19 era
2021, International Journal of CardiologyMissed Acute Myocardial Infarction (MAMI) in a rural and regional setting
2019, IJC Heart and VasculatureCitation Excerpt :If thrombolysis is delivered in a timely fashion, followed by transfer to a percutaneous coronary intervention (PCI) capable hospital, this provides outcomes similar to primary PCI, which is recommended where facilities are available [5]. The impact of delay in treatment and failure to provide reperfusion doubles mortality, and impacts on morbidity outcomes [6]. Differing clinical presentations and organisational factors can make the diagnosis of ACS challenging for clinicians, resulting in some patients not receiving appropriate care [7].
Non-reperfused ST-elevation myocardial infarction: notions from a low-to-middle-income country
2023, Archivos de Cardiologia de MexicoThe use of reperfusion therapy in transition countries without fully applicable pharmacoinvasive strategy
2022, Vojnosanitetski PregledA good report card, but there is room for improving care for patients with myocardial infarction
2021, Medical Journal of Australia